X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1234) 1234
Publication (164) 164
Book Review (22) 22
Book / eBook (10) 10
Book Chapter (6) 6
Conference Proceeding (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (960) 960
male (641) 641
neurosciences (636) 636
rats (561) 561
excitatory amino acid antagonists - pharmacology (502) 502
index medicus (474) 474
pharmacology & pharmacy (465) 465
humans (457) 457
glutamate (295) 295
dose-response relationship, drug (281) 281
mice (279) 279
female (254) 254
rats, sprague-dawley (247) 247
receptors, n-methyl-d-aspartate - antagonists & inhibitors (209) 209
excitatory amino acid antagonists - therapeutic use (204) 204
psychiatry (192) 192
rats, wistar (154) 154
neurons - drug effects (151) 151
disease models, animal (150) 150
clinical neurology (144) 144
methyl aspartate (141) 141
brain (139) 139
excitatory amino acid agonists - pharmacology (134) 134
dizocilpine maleate - pharmacology (130) 130
schizophrenia (125) 125
excitatory amino acid antagonists - pharmacokinetics (115) 115
ketamine (114) 114
receptors, n-methyl-d-aspartate - metabolism (113) 113
brain - metabolism (112) 112
brain - drug effects (110) 110
neurons (108) 108
neuroprotective agents - pharmacology (108) 108
excitatory amino-acids (107) 107
excitatory amino acid antagonists - administration & dosage (106) 106
rat (103) 103
analysis (99) 99
glutamic acid - metabolism (97) 97
motor activity - drug effects (97) 97
article (95) 95
biochemistry & molecular biology (95) 95
cells, cultured (92) 92
methyl-d-aspartate (91) 91
adult (90) 90
time factors (90) 90
memantine (89) 89
neurons - metabolism (89) 89
nmda receptor (89) 89
rat-brain (89) 89
behavior, animal - drug effects (88) 88
neurology (87) 87
nmda (83) 83
drug interactions (82) 82
neuroprotection (82) 82
mk-801 (80) 80
in vitro techniques (79) 79
ketamine - pharmacology (78) 78
hippocampus - drug effects (75) 75
long-term potentiation (75) 75
middle aged (75) 75
analysis of variance (70) 70
neuroprotective agents - therapeutic use (70) 70
pharmacology/toxicology (69) 69
biomedicine (67) 67
anticonvulsants - pharmacology (65) 65
in-vitro (65) 65
pharmacology (65) 65
drug therapy (64) 64
dopamine (63) 63
rodents (63) 63
excitatory amino acid antagonists - adverse effects (62) 62
hippocampus (62) 62
epilepsy (60) 60
expression (60) 60
mice, inbred c57bl (60) 60
prefrontal cortex (60) 60
double-blind (59) 59
gaba (58) 58
memantine - pharmacology (58) 58
double-blind method (57) 57
n-methylaspartate - pharmacology (57) 57
neurotoxicity (57) 57
synaptic transmission - drug effects (57) 57
alzheimer's disease (56) 56
pharmacokinetics (56) 56
hippocampus - metabolism (55) 55
receptors, n-methyl-d-aspartate - physiology (55) 55
treatment outcome (55) 55
glutamate receptors (54) 54
nmda receptors (54) 54
antagonists (53) 53
excitotoxicity (53) 53
physiological aspects (53) 53
central-nervous-system (52) 52
patch-clamp techniques (52) 52
receptors, n-methyl-d-aspartate - drug effects (52) 52
excitatory amino acids (51) 51
excitatory postsynaptic potentials - drug effects (51) 51
in-vivo (51) 51
receptors (51) 51
receptors, metabotropic glutamate - metabolism (50) 50
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Neuropharmacology, ISSN 0028-3908, 07/2014, Volume 82, pp. 161 - 173
Previous work has suggested that activation of mGlu5 receptor augments NMDA receptor function and thereby may constitute a rational approach addressing... 
Schizophrenia | Positive allosteric modulator | Neurotoxicity | Metabotropic glutamate receptor | Antipsychotic activity | METABOTROPIC GLUTAMATE-RECEPTOR | PROTEIN-KINASE-C | NEGATIVE SYMPTOMS | FRAGILE-X | NEUROSCIENCES | PREFRONTAL CORTEX | NEURONAL DAMAGE | PHARMACOLOGY & PHARMACY | LONG-TERM POTENTIATION | BINDING-SITES | ACUTE STRESS | METHYL-D-ASPARTATE | Antipsychotic Agents - toxicity | Neurons - pathology | Cricetulus | Rats, Wistar | Benzamides - pharmacokinetics | Allosteric Regulation | Humans | Male | Excitatory Amino Acid Agents - pharmacokinetics | Mice, 129 Strain | Necrosis - pathology | Excitatory Amino Acid Agents - chemistry | Oxadiazoles - toxicity | Receptor, Metabotropic Glutamate 5 - genetics | Necrosis - physiopathology | Neurotoxicity Syndromes - pathology | Neurons - physiology | Female | Cell Death - drug effects | Neurons - drug effects | Oxadiazoles - chemistry | Oxadiazoles - pharmacokinetics | Benzamides - chemistry | CHO Cells | Benzamides - toxicity | Brain - physiopathology | Cells, Cultured | Antipsychotic Agents - pharmacokinetics | Receptor, Metabotropic Glutamate 5 - metabolism | Rats, Sprague-Dawley | Mice, Knockout | Brain - drug effects | Excitatory Amino Acid Agents - toxicity | Animals | Antipsychotic Agents - chemistry | Cell Death - physiology | Neurotoxicity Syndromes - physiopathology | Brain - pathology | Methyl aspartate | Antipsychotic drugs | Glutamate | Index Medicus
Journal Article
Nature Communications, ISSN 2041-1723, 12/2018, Volume 9, Issue 1, pp. 4 - 9
Journal Article
Molecular Psychiatry, ISSN 1359-4184, 08/2016, Volume 21, Issue 8, pp. 1063 - 1069
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 10/2010, Volume 53, Issue 19, pp. 7107 - 7118
Journal Article
EUROPEAN JOURNAL OF PHARMACOLOGY, ISSN 0014-2999, 11/2009, Volume 623, Issue 1-3, pp. 73 - 83
Journal Article
Brain Research, ISSN 0006-8993, 2015, Volume 1624, pp. 239 - 252
Journal Article
Synapse, ISSN 0887-4476, 02/2011, Volume 65, Issue 2, pp. 125 - 135
Two moderately lipophilic, high affinity ligands for metabotropic glutamate receptor subtype 1 (mGluR1) were radiolabeled with a positron‐emitting radioisotope... 
[18F]MK‐1312 | metabotropic glutamate receptor 1 | fluorine‐18 | monkey | positron emission tomography (PET) | Bmax | Metabotropic glutamate receptor 1 | Positron emission tomography (PET) | F]MK-1312 | Fluorine-18 | Monkey | B-max | fluorine-18 | [F-18]MK-1312 | IN-VIVO | METABOTROPIC GLUTAMATE RECEPTORS | ANTAGONISTS | BINDING | NEUROSCIENCES | NUCLEOPHILIC AROMATIC-SUBSTITUTION | Brain - diagnostic imaging | Humans | Indoles - chemical synthesis | Autoradiography - methods | Excitatory Amino Acid Agents - pharmacokinetics | Macaca mulatta | Positron-Emission Tomography | Receptors, Metabotropic Glutamate - metabolism | Excitatory Amino Acid Agents - chemistry | Brain - drug effects | Brain - metabolism | Dose-Response Relationship, Drug | Tissue Distribution | Excitatory Amino Acid Agents - chemical synthesis | Animals | Fluorine Radioisotopes - pharmacokinetics | Brain Mapping | Inhibitory Concentration 50 | Indoles - pharmacokinetics | Ligands | Triazoles - chemical synthesis | Triazoles - pharmacokinetics | Fluorine Radioisotopes - chemistry | Binding Sites - drug effects | Cerebellum | Brain | Brain slice preparation | Cortex | Radioisotopes | Putamen | Substantia grisea | Autoradiography | Lipophilic | Allosteric properties | Fluoride | Thalamus | Glutamic acid receptors (metabotropic) | Positron emission tomography | Hippocampus | Synapses | Tracers
Journal Article
Expert Opinion on Investigational Drugs, ISSN 1354-3784, 04/2010, Volume 19, Issue 4, pp. 555 - 561
Journal Article
Journal Article
Annals of Surgery, ISSN 0003-4932, 08/2013, Volume 258, Issue 2, pp. 262 - 269
OBJECTIVE:We conducted a pharmacokinetic (PK) study and a pharmacodynamic (PD) study to assess whether Roux-en-Y gastric bypass (RYGB) surgery is associated... 
furosemide | oral cocktail | CYP3A | gastric bypass | drug metabolism | SURGERY | FATTY LIVER-DISEASE | WEIGHT-LOSS | TRENDS | P-GLYCOPROTEIN | OBESITY | INTESTINAL ADAPTATION | BARIATRIC SURGERY | ABSORPTION | HEPATIC STEATOSIS | Gastric Bypass | Diuretics - pharmacokinetics | Excitatory Amino Acid Antagonists - pharmacokinetics | Humans | Middle Aged | Tolbutamide - urine | Male | Caffeine - pharmacokinetics | Midazolam - urine | Anti-Ulcer Agents - pharmacokinetics | Young Adult | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Diuretics - urine | Diuretics - administration & dosage | Hypoglycemic Agents - pharmacokinetics | Administration, Oral | Furosemide - pharmacokinetics | Omeprazole - administration & dosage | Excitatory Amino Acid Antagonists - administration & dosage | Hypoglycemic Agents - urine | Omeprazole - urine | Central Nervous System Stimulants - pharmacokinetics | Midazolam - blood | Dextromethorphan - urine | Adolescent | GABA Modulators - urine | Central Nervous System Stimulants - urine | Dextromethorphan - administration & dosage | Furosemide - administration & dosage | Tolbutamide - administration & dosage | Tolbutamide - pharmacokinetics | Caffeine - administration & dosage | Omeprazole - blood | GABA Modulators - pharmacokinetics | Midazolam - administration & dosage | Anti-Ulcer Agents - blood | Chromatography, High Pressure Liquid | Case-Control Studies | Excitatory Amino Acid Antagonists - urine | Hypoglycemic Agents - blood | Tandem Mass Spectrometry | Biotransformation | Adult | Female | Dextromethorphan - pharmacokinetics | Furosemide - urine | Caffeine - urine | Caffeine - blood | GABA Modulators - administration & dosage | GABA Modulators - blood | Omeprazole - pharmacokinetics | Anti-Ulcer Agents - urine | Midazolam - pharmacokinetics | Anti-Ulcer Agents - administration & dosage | Dextromethorphan - blood | Excitatory Amino Acid Antagonists - blood | Tolbutamide - blood | Aged | Central Nervous System Stimulants - blood | Pharmacokinetics | Central Nervous System Stimulants - administration & dosage
Journal Article
Psychological Medicine, ISSN 0033-2917, 05/2016, Volume 46, Issue 7, pp. 1459 - 1472
Background. Ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists (NMDAR antagonists) recently demonstrated antidepressant efficacy for the... 
depression | meta-analyses | ketamine | Bipolar depression | N-methyl-d-aspartate receptor antagonists | trajectories | TREATMENT-RESISTANT DEPRESSION | PSYCHIATRY | ADD-ON TRIAL | RANDOMIZED CONTROLLED-TRIAL | MAJOR DEPRESSION | IV KETAMINE | PSYCHOLOGY, CLINICAL | PSYCHOLOGY | PROOF-OF-CONCEPT | INTRAVENOUS KETAMINE | N-methyl-D-aspartate receptor antagonists | ANTIDEPRESSANT EFFICACY | CHANNEL BLOCKER | RATING-SCALE | Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors | Excitatory Amino Acid Antagonists - pharmacokinetics | Humans | Excitatory Amino Acid Antagonists - administration & dosage | Excitatory Amino Acid Antagonists - pharmacology | Bipolar Disorder - drug therapy | Ketamine - administration & dosage | Ketamine - adverse effects | Outcome Assessment (Health Care) - statistics & numerical data | Ketamine - pharmacokinetics | Antidepressive Agents - administration & dosage | Antidepressive Agents - pharmacology | Antidepressive Agents - adverse effects | Antidepressive Agents - pharmacokinetics | Ketamine - pharmacology | Excitatory Amino Acid Antagonists - adverse effects | Depressive Disorder, Major - drug therapy | Discontinued | Depressive personality disorders | Intravenous administration | Toxicity | Clinical trials | Glutamic acid receptors | Mental depression | Dosage | Clinical outcomes | Randomized controlled trials | Confidence intervals | Psychotropic drugs | Hostility | Remission | Safety | Antidepressant drugs | Bipolar affective disorder | Efficacy | Depression | N-Methyl-D-aspartic acid receptors | Meta-analysis | Refractory depression | Side effects | Ketamine | Psychopharmacology | Superiority | Index Medicus
Journal Article
Clinical Interventions in Aging, ISSN 1176-9092, 09/2015, Volume 10, pp. 1457 - 1466
The use of multi drug regimens among the elderly population has increased tremendously over the last decade although the benefits of medications are always... 
Antipsychotic | AChEIs | Alzheimer | Drug–drug interaction | RISK-FACTORS | CHOLINESTERASE-INHIBITORS | ELDERLY-PEOPLE | GERIATRICS & GERONTOLOGY | CO-MORBIDITY | PHARMACOKINETIC CHANGES | AGE-RELATED-CHANGES | DONEPEZIL HCL | antipsychotic | CONSENSUS STATEMENT | drug-drug interaction | CLINICAL-PRACTICE | ATYPICAL ANTIPSYCHOTIC MEDICATIONS | Cholinesterase Inhibitors - pharmacokinetics | Excitatory Amino Acid Antagonists - pharmacokinetics | Anti-Arrhythmia Agents - pharmacology | Antipsychotic Agents - adverse effects | Humans | Drug Interactions | Antidepressive Agents - pharmacology | Excitatory Amino Acid Antagonists - adverse effects | Memantine - pharmacokinetics | Memantine - pharmacology | Benzodiazepines - pharmacology | Alzheimer Disease - drug therapy | Benzodiazepines - pharmacokinetics | Excitatory Amino Acid Antagonists - pharmacology | Antipsychotic Agents - pharmacokinetics | Anti-Arrhythmia Agents - pharmacokinetics | Cholinesterase Inhibitors - pharmacology | Anti-Arrhythmia Agents - adverse effects | Cholinesterase Inhibitors - adverse effects | Aged | Benzodiazepines - adverse effects | Antidepressive Agents - adverse effects | Antipsychotic Agents - pharmacology | Antidepressive Agents - pharmacokinetics | Memantine - adverse effects | Complications and side effects | Antipsychotic drugs | Drug interactions | Analysis | Research | Drug therapy | Alzheimer's disease | Health aspects | Psychosis | Delirium | Cytochrome | Psychotropic drugs | Older people | Cognitive ability | Alzheimers disease | Drug dosages | Age | Geriatrics | Dementia
Journal Article